139 related articles for article (PubMed ID: 6489392)
21. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
[TBL] [Abstract][Full Text] [Related]
22. Effects of haloperidol on human plasma magnesium.
Jabotinsky-Rubin K; Durst R; Levitin LA; Moscovich DG; Silver H; Lerner J; Van Praag H; Gardner EL
J Psychiatr Res; 1993; 27(2):155-9. PubMed ID: 8366466
[TBL] [Abstract][Full Text] [Related]
23. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
Levinson I; Levine S
Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
[No Abstract] [Full Text] [Related]
24. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
[TBL] [Abstract][Full Text] [Related]
25. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
[TBL] [Abstract][Full Text] [Related]
26. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
27. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
28. The relationship between plasma haloperidol concentrations and clinical results.
Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
[No Abstract] [Full Text] [Related]
29. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Arvanitis LA; Miller BG
Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
[TBL] [Abstract][Full Text] [Related]
30. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
31. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
[TBL] [Abstract][Full Text] [Related]
32. Haloperidol plasma levels and acute clinical change in schizophrenia.
Coryell W; Kelly M; Perry PJ; Miller DD
J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
[TBL] [Abstract][Full Text] [Related]
33. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
34. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
[TBL] [Abstract][Full Text] [Related]
35. The relationship between haloperidol blood levels and clinical responses.
Itoh H; Yagi G; Fujii Y; Iwamura K; Ichikawa K
Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):285-92. PubMed ID: 6539935
[TBL] [Abstract][Full Text] [Related]
36. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
Lahdelma RL; Appelberg B; Kuoppasalmi K; Katila H; Rimón R
Eur Neuropsychopharmacol; 1991 Dec; 1(4):535-40. PubMed ID: 1688013
[TBL] [Abstract][Full Text] [Related]
37. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of determination of plasma haloperidol levels.
Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.
Smith RC; Baumgartner R; Shvartsburd A; Ravichandran GK; Vroulis G; Mauldin M
Psychopharmacology (Berl); 1985; 85(4):449-55. PubMed ID: 2862652
[TBL] [Abstract][Full Text] [Related]
40. Drug-responsive symptoms during early neuroleptic treatment.
Mazure CM; Nelson JC; Jatlow PI; Bowers MB
Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
